Core Insights - The application and promotion of AI medical imaging devices in domestic clinical settings face challenges, despite recent approvals of several domestically developed medical devices by the National Medical Products Administration [1][4] - The latest approved devices exhibit significant features of mobility and intelligence, with AI functionality becoming a key focus for companies in their R&D efforts [1][3] Industry Developments - Recently, two AI-enabled medical imaging devices were approved, including a mobile MRI system and a large-aperture standing CT, which break traditional usage barriers and provide imaging support for various medical scenarios [1][3] - Major international and domestic companies, including GE Healthcare, Siemens Healthineers, and Philips, are increasing their R&D investments in AI medical imaging devices, showcasing advanced AI-integrated diagnostic equipment at recent trade shows [3][4] Technological Advancements - AI is identified as a crucial direction for the development of MRI devices, with companies planning to enhance imaging capabilities through AI optimization and intelligent segmentation of lesions [3][5] - Siemens Healthineers has developed an AI cardiovascular ultrasound system that utilizes a vast database of heart images to improve diagnostic accuracy and consistency [4][5] Market Challenges - Despite the technological advancements, the clinical application of AI medical imaging devices is primarily research-focused, with unclear pricing structures for AI-enabled devices hindering their adoption in hospitals [4][6] - The integration of AI in medical imaging is limited by existing medical models and reimbursement systems, indicating a gap between China and the United States in the deployment of AI medical devices [6]

Group 1: Event Overview - The 2025 China International Service Trade Fair (CIFTIS) successfully concluded on September 14, showcasing the health and wellness services sector for the fifth consecutive year with the theme "Smart Leading Future, Healthy Life" [1] - The participation rate of Fortune 500 companies reached 54%, with an internationalization rate of 53% [1] - Major global companies such as GE Healthcare, Siemens Healthineers, and Mindray participated, alongside first-time exhibitors like Elsevier and Tianjin Pengruili Hospital [1] Group 2: AI and Medical Innovations - The "AI Fundus Camera," developed by Tongren Hospital and Yingtong Technology, allows for rapid retinal imaging and risk assessment for chronic diseases using AI technology [2] - The "Qinghua Chang Geng AI Hepatobiliary Super Doctor," developed by Tsinghua University and Qinghua Huabao, provides intelligent consultations and treatment recommendations for liver and biliary diseases [3] - The AI application base in Beijing aims to enhance medical services through a comprehensive service system for medical institutions and technology companies [4] Group 3: International Expansion of Medical Device Companies - The CIFTIS serves as a significant platform for showcasing innovations in the service trade sector and promoting international cooperation [5] - Companies like United Imaging have successfully entered high-end markets in over 90 countries, achieving a 3.5 times revenue growth in overseas markets from 2020 to 2022 [5] - Mindray Medical has expanded its products and solutions to over 190 countries, with 62 overseas subsidiaries in 40 countries [6] Group 4: Strategic Market Development - Stronglink Intelligent Innovation has initiated its overseas market strategy, achieving progress in AI catheter shaping robot certification and market promotion [7] - The CIFTIS provides a vital opportunity for companies to connect with foreign clients and explore international market opportunities without leaving the country [7]